TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01932333
Drug: JNJ-40411813 100 mg
Normalized name: JNJ-40411813
DrugBank: JNJ-40411813 (DB12059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 2: Participants will receive 100 mg of JNJ-40411813 (1 capsule X 100 mg) once a day on Day 1 in Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 in Period 2 orally (by mouth).
Study: NCT00931086
Drug: belimumab
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV 10mg/kg q28days
Study: NCT00838526
Drug: Ranitidine
Normalized name: Ranitidine
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg capsule, taken orally, twice daily for 26 weeks.
Study: NCT03447639
Drug: Povidone-iodine irrigation
Normalized name: povidone-iodine Irrigation Product
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose, 60 cc of 2% povidone-iodine indwelling for 10 minutes prior to catheter removal using aseptic technique
Study: NCT01963741
Drug: leukotriene D4
Normalized name: Leukotriene D4
DrugBank: Leukotriene D4 (DB11858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal challenge using 16% ethanol diluent, the concentration of which corresponded to the highest concentration of LTD4, was undertaken for exclusion of subjects hypersensitive to ethanol or saline. The LTD4 challenge could be initiated provided that NAR increase was \<30%. Ranges of 4 to 16 mcg.mL-1 LTD4 diluents were applied for a double-fold increment approach at intervals of 6 minutes.
Study: NCT01963741
Drug: histamine
Normalized name: Histamine
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasal challenge using 0.9% saline, was undertaken for exclusion of subjects hypersensitive to saline. The histamine nasal challenge could be initiated provided that NAR increase was \<30%. Ranges of 0.4 to 3.2 mg.mL-1 histamine diluents were applied for a double-fold increment approach at intervals of 3 minutes.
Study: NCT03352674
Drug: Insulin Glargine Ezelin
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Glargine (Ezelin) once daily at individually adjusted dose
Study: NCT03352674
Drug: Insulin Glargine Pen Injector [Lantus]
Normalized name: insulin glargine Pen Injector [Lantus]
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Glargine (Lantus) once daily at individually adjusted dose
Study: NCT05046262
Drug: Calcium chloride
Normalized name: Calcium Chloride
DrugBank: Calcium chloride (DB01164)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium electroporation
Study: NCT02860546
Drug: TAS-102
Normalized name: TAS-102
DrugBank: TAS-102 (DB08937)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One Arm Only (of TAS 102 plus nivolumab)
Study: NCT02860546
Drug: nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One Arm Only (of TAS 102 plus nivolumab)
Study: NCT02035371
Drug: Faster-acting insulin aspart
Normalized name: diphenhydramine
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A single dose will be administered subcutaneously (s.c. under the skin)
Study: NCT02035371
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A single dose will be administered subcutaneously (s.c. under the skin)
Study: NCT01132729
Drug: Valacyclovir Hydrochloride
Normalized name: Valacyclovir Hydrochloride
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000 mg caplet
Study: NCT00842673
Drug: ST101
Normalized name: ST101 peptide
DrugBank: ST-101 (DB12621)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg; administered once/day
Study: NCT00842673
Drug: ST101
Normalized name: ST101 peptide
DrugBank: ST-101 (DB12621)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg; administered once/day
Study: NCT00842673
Drug: ST101
Normalized name: ST101 peptide
DrugBank: ST-101 (DB12621)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mg; administered once/day
Study: NCT00122382
Drug: Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: abatacept 10 mg/kg IV monthly, methotrexate weekly, for 24 months
Study: NCT01930682
Drug: Alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alteplase is given as a intravenous bolus (8-mg) followed by 42 mg iv gtt in 90 min.
Study: NCT01927120
Drug: IL-2
Normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A subcutaneous injection will be administered 3 times a week (separated by at least 1 day between injections), from day 0 to +90 (+/- 7 days).
Study: NCT01927120
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Will be administered at 0.01 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3
Study: NCT01927120
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Orally on day -1. The dose for loading is 12 mg by mouth (PO)
Study: NCT01099592
Drug: Citalopram
Normalized name: Citalopram
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients will take citalopram once daily. Medication will be commercial tablets of 20 mg or 40 mg. All patients will start on a half dose of 10 mg and, if there are no severe side effects, will be increased to 20 mg after 1 week, and if the HAMD-24 at 6 weeks is not \< 8, the dose will increase to 40 mg.
Study: NCT00748592
Drug: PD 0200390
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects in this arm will be administered 3 capsules totaling 5 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
Study: NCT00748592
Drug: PD 0200390
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects in this arm will be administered 3 capsules totaling 15 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
Study: NCT00748592
Drug: PD 0200390
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects in this arm will be administered 3 capsules totaling 30 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
Study: NCT02205463
Drug: KD019
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04935541
Drug: Dexmedetomidine infusion
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After Dexmedetomidine infusion was given for 10 minutes, local anesthesia was applied by the surgeon. Peribulbar block and periorbital infiltration application were performed by applying a mixture of lidocaine (Jetokain, Adeka, Turkey) and 1/200000 adrenaline. After the local anesthetic agent was applied by the surgeon, orbital compression was provided for 5 minutes with maximum pressure to block the eyelid movements. Cataract surgery procedures of all patients included in the study were performed by the same surgeon.
Study: NCT01288079
Drug: TC-5214
Normalized name: TC-6987
DrugBank: TC-6987 (DB14854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral, twice daily for 8 weeks
Study: NCT01288079
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule, oral, once daily
Study: NCT00528047
Drug: PRLX 93936
Normalized name: PRLX 93936
DrugBank: PRLX 93936 (DB06098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRLX 93936 will be administered intravenously over one hour daily for 5 days.
Study: NCT04777227
Drug: Lidocaine injection
Normalized name: lidocaine Injection
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2% (20mg/ml) lidocaine solution
Study: NCT04777227
Drug: Physiological water injection
Normalized name: WATER FOR INJECTION
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sterile sodium chloride water
Study: NCT02397512
Drug: application of lactulose
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will ingest 50g of lactulose once
Study: NCT02350023
Drug: Topical latanoprost 0.005%
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Local application of the drug on affected skin/scalp
Study: NCT02350023
Drug: Topical betamethasone 0.05%
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local application of the drug on affected skin/scalp
Study: NCT03153163
Drug: Trastuzumab Emtansine
Normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab emtansine will be administered by IV infusion at a dose of 3.6 milligrams per kilogram (mg/kg) of body weight, every three weeks (Q3W) until death, disease progression or unmanageable toxicity.
Study: NCT01622673
Drug: Raltegravir
Normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Raltegravir 400 mg oral tablet taken with 240 mL water every 12 hours~Throughout the study, participants will continue to take raltegravir along with their other HIV medications. On the day of co-dosing and intensive pharmacokinetic (PK) sampling, raltegravir will be dosed in the morning in a fasted state in all periods.
Study: NCT00305474
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone will be given in low dosage to a random sample of family members of Schizophrenic patients
Study: NCT00659451
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablets; 50, 100 mg; od; 12 months
Study: NCT00659451
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablets; 5, 10 mg; od; 12 months
Study: NCT02847260
Drug: Remodulin
Normalized name: Remodulin
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment will be initiated whilst hospitalized at approximately 2.0 ng/kg/min with dose increments of 1- 2 ng/kg/min approximately every 12 hours according to clinical response and tolerability. Following subject discharge, the dose rate is increased by 1-2 ng/kg/min with dose increments separated by at least 24 hours. When a dose rate of 20 ng/kg/min is achieved dose increments can be increased at a rate of up to 4 ng/kg/min with dose increments separated by at least 24 hours depending on tolerability. The aim is to achieve a dose rate of at least 10, 20 and 30 ng/kg/min by the end of weeks 1, 4 and 12, respectively and a dose rate by the end of week 16 that achieves pre-defined treatment goals subject to clinical response and tolerability.
Study: NCT00929968
Drug: Fluticasone
Normalized name: Fluticasone
DrugBank: Fluticasone (DB13867)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00443729
Drug: Comparator: raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: raltegravir 400 milligram (mg) by mouth (PO) twice daily (b.i.d) for up to 48 weeks of treatment
Study: NCT00443729
Drug: Comparator: lopinavir (+) ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lopinavir (+) ritonavir 400/100 mg by mouth (PO) twice daily (b.i.d.) for up to 48 weeks of treatment
Study: NCT02748304
Drug: sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sorafenib 400mg bid po
Study: NCT02748304
Drug: aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: aspirin 100mg qd po
Study: NCT00443690
Drug: rolofylline
Normalized name: Rolofylline
DrugBank: Rolofylline (DB12670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rolofylline 30 mg IV QD; 3 days
Study: NCT02969252
Drug: Rifamycin SV-MMX® 600
DrugBank: Rifamycin (DB11753)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00618111
Drug: Granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03597295
Drug: Retifanlimab
Normalized name: Retifanlimab
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retifanlimab 500 milligrams (mg) intravenously every 4 weeks (Q4W).
Study: NCT01841684
Drug: Anacetrapib
Normalized name: Anacetrapib
DrugBank: Anacetrapib (DB06630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tablet orally, once daily for 12 weeks
Study: NCT04810208
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel in NanoZolid formulation, for intratumoural injection
Study: NCT02090088
Drug: Not applicable- observational study
Normalized name: sodium bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00659711
Drug: Januvia (Sitagliptin) 100 mg
Normalized name: Januvia
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The first group will be started on 100 mg sitagliptin daily for 12 weeks
Study: NCT02426502
Drug: conversion of non-immunosuppressant drugs to once daily
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Conversion of anti-hypertensive medications: converted to once daily alternatives with the goal of maintaining blood pressure at the same or lower level prior to conversion.~* Conversion of all other medications: changed to once daily formulations of the same medication or a once daily alternative.
Study: NCT02426502
Drug: Conversion to once daily MPA
Normalized name: polyurethane-34 (55 MPA)
DrugBank: Urethane (DB04827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Conversion to once daily MPA: Patients taking mycophenolate mofetil (MMF) will receive 1.0 gram once daily, while patients receiving Myfortic will receive 720 mg once daily.~* Conversion to once daily Myfortic: Patients prescribed proton pump inhibitors (PPIs) and MMF will be switched to equivalent dose Myfortic for a period of one month prior to conversion to once daily MPA.~* Patients taking azathioprine will be maintained on the same dose.~* Patients will be maintained on the same prednisone dose.
Study: NCT00940628
Drug: orlistat [Xenical]
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 120mg po tid
Study: NCT03963193
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide 100mg/m\^2 ivggt on days 1, 2, 3, Cisplatin 25mg/m\^2 ivggt on days 1, 2, 3, repeated every 21 days.
Study: NCT03963193
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan 65 mg/m\^2 ivggt on days 1, 8, Cisplatin 30 mg/m\^2 ivggt on days 1, 8, repeated every 21 days.
Study: NCT02716961
Drug: Gemcitabine, cisplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients who were pathologically confirmed as moderate-high risk NMIBC. Epirubicin was immediately instilled in 24h after TURBT and regularly conducted for a year. GC scheme systematic chemotherapy was underwent 5 days after TURBT, which contained gemcitabine 1000-1200mg/m2. Cisplatin (70mg/m2) was intravenous dripped in the first and 8th day after TURBT. Intravenous rehydration was conducted in the second day.
Study: NCT01380561
Drug: asimadoline
Normalized name: Asimadoline
DrugBank: Asimadoline (DB05104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg \[14\]C labelled asimadoline Day 1 then 7 doses 0.5 mg asimadoline bid beginning on Day 2 and ending on Day 5.
Study: NCT03932513
Drug: inarigivir soproxil
Normalized name: Inarigivir soproxil
DrugBank: Inarigivir soproxil (DB15063)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inarigivir 200mg and 400mg oral tablets, once daily
Study: NCT02840929
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03177824
Drug: Sildenafil Citrate 25Mg Tab
Normalized name: SILDENAFIL CITRATE 25MG TAB
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group 1, consists of 30 patients who will receive Sildenafil citrate (25mg) tab (Silden, Epico, Egypt) 3times daily till the time of delivery, followed by repeating the Doppler US scan serially to detect changes in the measured indices and then assess the neonatal outcome after delivery as regard birth weight and APGAR score.
Study: NCT00199420
Drug: Istradefylline (KW-6002)
Normalized name: istradefylline
DrugBank: Istradefylline (DB11757)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03405831
Drug: Ivabradine
Normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ivabradine, oral tablets, 5 mg, coated in gelatine capsules to ensure blinding, 1 capsule twice a day, for a period of 12 weeks
Study: NCT04464174
Drug: Ipatasertib
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipatasertib administered orally (400 mg) once a day, from day 1 to day 14, and rest from day 15 to day 21 of every 21-day cycle
Study: NCT04464174
Drug: Eribulin
Normalized name: Eribulin
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin 1.23 mg/m2 administered intravenously Days 1 and 8 of every 21-day cycle
Study: NCT04464174
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC5 administered intravenously day 1 of every 21-day cycle
Study: NCT04464174
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine administered intravenously (1000 mg/m2) at days 1 and 8 of every 21-day cycle
Study: NCT04369391
Drug: moxifloxacin 400 mg
Normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: moxifloxacin tablet 400 mg
Study: NCT01797874
Drug: Pazopanib
Normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Experimental
Study: NCT00517504
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * 1-week single blind placebo lead-in phase.~* step-wise single blind titration of MPH at 1.25 mg bid for the first week, 2.5 mg bid for the second week , 5 mg bid for the third week, 7.5 mg bid for the fourth week and 10 mg bid for the 5th week.~Dose increased if room for improvement in child's symptoms and no clinically important side effects. Dose not increased if no room for improvement in child's symptoms or if clinically important side effects.~After single blind titration, child enters a 4-week double-blind randomized crossover study with placebo and child's best dose that produced maximal effect with minimal side effects, with each child serving as his/her own control.
Study: NCT01974622
Drug: Visudyne
Normalized name: Visudyne
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Half fluence verteporfin
Study: NCT02015728
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide combined with Etoposide is considered the best available combination of low-dose oral cytotoxic agents for patients with refractory or recurrent CNS tumors.
Study: NCT02015728
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide combined with Temozolomide is considered the best available combination of low-dose oral cytotoxic agents for patients with refractory or recurrent CNS tumors.
Study: NCT02015728
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib is a broad-spectrum kinase inhibitor.
Study: NCT02015728
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus is an mTOR pathway inhibitor.
Study: NCT02015728
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib is a tyrosine kinase inhibitor of the ERBB family of proteins.
Study: NCT02015728
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dasatinib is a broad spectrum SRC inhibitor.
Study: NCT02352701
Drug: Chongkundang Amoxicillin Cap. 500mg
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin 1000mg, BID dosage form : capsule
Study: NCT03604224
Drug: Canagliflozin 300 mg
Normalized name: canagliflozin 300 MG
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants who are initiated on canagliflozin 300 mg will be observed. No study treatment will be administered as a part of this study.
Study: NCT01037218
Drug: Udenafil
Normalized name: udenafil
DrugBank: Udenafil (DB06267)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets via oral administration before an attempt at sexual intercourse.
Study: NCT00150735
Drug: LEVETIRACETAM
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04505670
Drug: Donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: donepezil orally 5mg
Study: NCT03024502
Drug: Clotrimazole
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration intravaginal of clotrimazol, 1x/day, 7 days
Study: NCT00897715
Drug: Rilonacept
Normalized name: Rilonacept
DrugBank: Rilonacept (DB06372)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 160 mg of rilonacept administered subcutaneously once a week for 12 weeks
Study: NCT01268553
Drug: Treprostinil
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Transition to inhaled treprostinil
Study: NCT02591277
Drug: Harvoni
Normalized name: Harvoni
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Harvoni (90/400 mg) FDC tablet administered orally once daily
Study: NCT01404767
Drug: Esmolol
Normalized name: Esmolol
DrugBank: Esmolol (DB00187)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baseline treatment consists of a bolus of 500ug/kg/min followed by an infusion of 50ug/kg/min for 4 minutes and titrating in increment of 50ug/kg/min up to a maximum of 300ug/kg/min to maintain a HR within 10% of the target HR (≤ 70 bpm), which is 70± 7 bpm.
Study: NCT01404767
Drug: Metoprolol
Normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The night and morning before surgery, the patients in the metoprolol arm will receive their standard dose of beta blocker metoprolol.These patients will receive their daily beta blockers orally or via nasogastric tube postoperatively if they are NPO (Group A).